Premium
Once‐Daily Aminoglycoside in the Treatment of Enterococcus faecalis Endocarditis: Case Report and Review
Author(s) -
Tam Vincent H.,
McKin Peggy S.,
Levine Donald P.,
Brandel Susan M.,
Rybak Michael J.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.13.1116.35029
Subject(s) - endocarditis , enterococcus faecalis , contraindication , medicine , gentamicin , enterococcus , aminoglycoside , antibiotics , intensive care medicine , surgery , microbiology and biotechnology , pathology , bacteria , biology , staphylococcus aureus , alternative medicine , genetics
Once‐daily administration of aminoglycosides (ODA) is effective and safe for many indications. By optimizing pharmacodynamic principles, it enhances bactericidal activity and minimizes toxicity. Its use for the treatment of enterococcal infection is controversial, however, and results of in vitro studies and animal models of endocarditis are conflicting. To date, no case reports or clinical trials have examined its utility in human enterococcal endocarditis. A patient with right‐sided endocarditis caused by Enterococcus faecalis was managed by once‐daily gentamicin. Clinical and bacteriologic cures of this patient raise questions as to whether enterococcal endocarditis should be regarded as contraindication to ODA. The clinical utility of ODA in this disease deserves further investigation.